The cell and gene therapy segment is one of the fastest growing segments in the biopharmaceutical space.While the science behind the therapy has grown by leaps and bounds on the back of decades worth of research, manufacturing has unfortunately lagged behind.
To fully harness the curative potential of these therapies and ensure greater reach and affordability to patients, it is imperative that aggressive investments in manufacturing technology and capacity are made today.Investments in manufacturing technology advancements including automation, single-use technologies, and GMP-in-a-box, will not only enable operational efficiency gains but also reduce project costs, generating benefits which can be transferred directly to the patients.
A large part of this growth in the cell and gene therapy product pipeline is being driven by small and mid-sized biotechs that depend on CDMOs to mitigate product development risks and diffuse infrastructure investments to be able to build future products pipeline.This research service focuses on the critical role being played by CDMOs in not only supporting new product research and development but also in creating standardized manufacturing protocols.
Additionally, the study explores different cross-sections of the market and discusses market dynamics for autologous and allogeneic solutions for cell and gene therapies and for products being manufactured for clinical trial use and for commercial markets. The variability in market dynamics, manufacturing protocols, and business models across cross-sections is high. Therefore, the study also covers the emergence of non-traditional CDMOs that have thrived as a result of this variability. The study also provides a comprehensive and critical analysis of nationally coordinated efforts towards infrastructure development and the rise of academic institutes and hospitals in meeting not only the demand from clinics, but also the demand of the commercial market. The study also analyses the growth of specialist CDMOs focusing on vectors and plasmids, for instance. The captures the regional outlook for growth based on the currently installed capacities as well as the pipeline investments being made towards expansion. Lastly, the study tracks growth opportunities across the entire product development spectrum from supply chain to upstream and downstream manufacturing.
Our reports have been used by over 10K customers, including:
Hepatocyte Growth Factor - Pipeline Review, H2 2020 Summary According to the recently published report ’Hepatocyte Growth Factor - Pipeline Review, H2 2020’; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. Hepatocyte Growth...
Viral Vector & Plasmid DNA Manufacturing Market Research Report by Type (Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA), by Indication (Cancer, Genetic Disorder, and Infectious Disease), by Workflow, by Application, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the cell and gene therapy market are Gilead Sciences, Bristol-Myers Squibb, Novartis AG, Amgen, Merck, Organogenesis Holdings, Dendreon, Vericel, Bluebird Bio and Fibrocell Science. The global cell and gene therapy market is expected to decline from $6.68 billion in 2019 to $6.92 billion in 2020 at a compound annual...
Executive Summary Global Gene Therapy Market was valued at USD 1221.84 Million in the year 2019. Escalating number of cases related to various chronic diseases including Cancer, Cardiovascular and Neurological Disorders, Alzheimer’s and Sickle Cell Diseases, with companies investing heavily in incorporating advanced technology...
Alpha L-Iduronidase - Pipeline Review, H2 2020 Summary Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene...
Erythropoietin Drugs Market Research Report by Drug Class (Biologics and Biosimilars), by Product (Darbepoetin-alfa, Epoetin-alfa, and Epoetin-beta), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and forecast across five major currencies...
Antithrombin Market Research Report by Formulation (Liquid and Lyophilized), by Source (Goat Milk and Human), by Type, by Route, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY,...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.